NCT02147886View on ClinicalTrials.gov

Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

November 30, 2016

Conditions
Machado-Joseph Disease / Spinocerebellar Ataxia 3
Interventions
DRUG

Cabaletta for IV infusion once weekly during 24 weeks

Cabaletta for IV infusion once weekly

DRUG

Cabaletta for IV infusion once weekly during 24 weeks

Trial Locations (1)

Unknown

Meir Medical Center, Kfar Saba

Sponsors
All Listed Sponsors
lead

Bioblast Pharma Ltd.

INDUSTRY

NCT02147886 - Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease | Biotech Hunter | Biotech Hunter